Marc Laisney
Novartis (Switzerland)(CH)
Publications by Year
Research Areas
Advanced Breast Cancer Therapies, Neuroendocrine Tumor Research Advances, HER2/EGFR in Cancer Research, T-cell and B-cell Immunology, RNA Research and Splicing
Most-Cited Works
- → Ribociclib Bioavailability Is Not Affected by Gastric pH Changes or Food Intake: In Silico and Clinical Evaluations(2017)78 cited
- → Physiologically Based Biopharmaceutics Modeling to Demonstrate Virtual Bioequivalence and Bioequivalence Safe-space for Ribociclib which has Permeation Rate-controlled Absorption(2021)51 cited
- → Pharmacological Inhibition of MALT1 Protease Leads to a Progressive IPEX-Like Pathology(2020)37 cited
- → Comparison of thein vitroandin vivometabolism of Cladribine (Leustatin, Movectro) in animals and human(2013)10 cited
- → 4. How solubility influences bioavailability(2019)2 cited
- → Oral splicing modulator branaplam in Huntington’s disease: a phase 2 randomized controlled trial(2026)
- → Abstract P1-14-05: Ribociclib dose recommendations for potential pharmacokinetic drug interaction and in special patient populations with organ impairment(2018)
- → Assessment of gastric pH changes and food intake on ribociclib bioavailability: In silico and clinical evaluations(2017)